<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>MYA Space | Dahlgaard Watson | Activity</title>
	<link>https://space.mya.co.uk/members/citycoffee71/activity/</link>
	<atom:link href="https://space.mya.co.uk/members/citycoffee71/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Dahlgaard Watson.</description>
	<lastBuildDate>Tue, 22 Sep 2026 18:26:47 +0100</lastBuildDate>
	<generator>https://buddypress.org/?v=10.2.0</generator>
	<language>en-GB</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">6b26da45c327eed845f63705badd252d</guid>
				<title>Dahlgaard Watson posted an update: More findings using Developed blotting, immunoprecipitation [&#133;]</title>
				<link>https://space.mya.co.uk/activity/p/1653605/</link>
				<pubDate>Mon, 16 Oct 2023 08:57:03 +0100</pubDate>

									<content:encoded><![CDATA[<p>More findings using Developed blotting, immunoprecipitation (IP), liquefied chromatography-tandem muscle size spectrometry (LC-MS/MS), along with immunohistochemistry (IHC) investigation revealed that your pp38-specific mAb 31G7 has large specificity along with <a href="https://www.selleckchem.com/products/gdc-0032.html" rel="nofollow ugc">Taselisib clinical trial</a> broad program risk of more research throughout MD chemistry&hellip;<span class="activity-read-more" id="activity-read-more-1653605"><a href="https://space.mya.co.uk/activity/p/1653605/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">6a8892eb1154ab7f5494da07fb8a44f2</guid>
				<title>Dahlgaard Watson posted an update: CHB patients who concluded treatment using 48weeks [&#133;]</title>
				<link>https://space.mya.co.uk/activity/p/1647617/</link>
				<pubDate>Sun, 15 Oct 2023 21:07:06 +0100</pubDate>

									<content:encoded><![CDATA[<p>CHB patients who concluded treatment using 48weeks peginterferon alpha2b±nucleoside analogue treatments (clinicaltrial.gov NCT01928511) were assessed from few days 72 regarding HBsAg loss. The actual predictive capacity of qHBsAg, qHBcrAg, HBV RNA as well as other parameters ended up looked into simply by univariate and multivariate logistic&hellip;<span class="activity-read-more" id="activity-read-more-1647617"><a href="https://space.mya.co.uk/activity/p/1647617/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">33055a8fe40591f697453996017b4260</guid>
				<title>Dahlgaard Watson became a registered member</title>
				<link>https://space.mya.co.uk/activity/p/1647333/</link>
				<pubDate>Sun, 15 Oct 2023 20:48:21 +0100</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>
<!--
Performance optimized by W3 Total Cache. Learn more: https://www.boldgrid.com/w3-total-cache/

Object Caching 0/128 objects using Redis
Page Caching using Disk: Enhanced 
Lazy Loading
Database Caching using Redis (Request-wide modification query)

Served from: space.mya.co.uk @ 2026-09-22 20:17:38 by W3 Total Cache
-->